Reportable Segment — Earnings (loss) in equity method investments
Business Segments · Earnings (loss) in equity method investmentsEli Lilly Reportable Segment — Earnings (loss) in equity method investments increased by 383.8% to $45.40M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 74.6%, from $26.00M to $45.40M. Over 2 years (FY 2022 to FY 2024), Reportable Segment — Earnings (loss) in equity method investments shows an upward trend with a -19.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Positive earnings indicate successful strategic partnerships, while losses may suggest underperformance of joint ventures.
Detailed definition
Represents the segment's share of the net income or loss from entities where the company exercises significant influence...
Peer comparison
Common in the pharmaceutical industry due to frequent R&D collaborations and joint ventures.
lly_segment_reportable_segment_earnings_loss_in_equity_method_investmentsHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$34.50M | -$34.50M | -$34.50M | -$34.50M | -$2.53M | -$2.53M | -$2.53M | -$2.53M | $13.70M | $25.90M | $26.00M | $24.20M | -$58.70M | -$16.00M | $45.40M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +92.7% | +0.0% | +0.0% | +0.0% | +642.6% | +89.1% | +0.4% | -6.9% | -342.6% | +72.7% | +383.8% |
| YoY Change | — | — | — | — | +92.7% | +92.7% | +92.7% | +92.7% | +642.6% | >999% | >999% | >999% | -528.5% | -161.8% | +74.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — earnings (loss) in equity method investments?
- Eli Lilly (LLY) reported reportable segment — earnings (loss) in equity method investments of $45.40M in Q3 2025.
- How has Eli Lilly's reportable segment — earnings (loss) in equity method investments changed year-over-year?
- Eli Lilly's reportable segment — earnings (loss) in equity method investments increased by 74.6% year-over-year, from $26.00M to $45.40M.
- What is the long-term trend for Eli Lilly's reportable segment — earnings (loss) in equity method investments?
- Over 2 years (2022 to 2024), Eli Lilly's reportable segment — earnings (loss) in equity method investments has grown at a -19.3% compound annual growth rate (CAGR), from -$138.00M to $89.80M.
- What does reportable segment — earnings (loss) in equity method investments mean?
- The segment's portion of profits or losses from companies it partially owns.